Doximity Inc (DOCS.NYSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 12 August 2026Deep analysis 5 July 202625 min read

Audit All Past Forecasts

12 AI Advisor Reports

Select an advisor report.

Michael Burry AI

The Vulture FrameworkAI Researcher

Rating

Strong Buy

5-Year Return Est.

+146.4%

DOCS.NYSE does not currently pay dividends

1. Investment Thesis — Base Case

Doximity is a misunderstood structural monopoly currently masquerading as a distressed asset. The stock has been punished for a temporary regulatory freeze in pharma budgets (TrumpRx) and a deliberate compression of operating margins as management funds its 'Free-99' clinical AI suite. However, the foundational economics remain elite: 89% gross margins, zero debt, and nearly 50% free cash flow conversion. At ~$22 per share, the market is offering a toll bridge to 80% of US physicians at a 7.5% FCF yield. As the company deploys its $500M buyback, it will accretively retire float. When pharma budgets eventually consolidate into the highest-ROI digital channels, and AI Search begins to monetize, EPS will compound rapidly on the reduced share count.

The 5% revenue growth in Q4 is a regulatory air-pocket, not terminal TAM saturation.
The 'Free-99' AI scribe strategy acts as a predatory moat, destroying competitor unit economics.
$317M in trailing FCF validates the accounting reality, mitigating the CFO departure risk.
A $500M open-market buyback provides a hard floor and mathematically forces future EPS growth.
The implied valuation is highly realistic; it requires no multiple expansion, only the mathematical realization of cash flow and float reduction.

Interactive forecast chart

Figure: Five-year interactive consensus forecast for Doximity, including the advisor-disagreement range and benchmark comparison. Sign in, verify your email, and use the required subscription to explore the chart.

AI Advisor 1

Michael Burry

Rating: strong_buy
Forecasted compounded return: +146.4%
Forecast anchor: 21.86 USD on July 2, 2026

Most reasonable investment thesis

Doximity is a misunderstood structural monopoly currently masquerading as a distressed asset. The stock has been punished for a temporary regulatory freeze in pharma budgets (TrumpRx) and a deliberate compression of operating margins as management funds its 'Free-99' clinical AI suite. However, the foundational economics remain elite: 89% gross margins, zero debt, and nearly 50% free cash flow conversion. At ~$22 per share, the market is offering a toll bridge to 80% of US physicians at a 7.5% FCF yield. As the company deploys its $500M buyback, it will accretively retire float. When pharma budgets eventually consolidate into the highest-ROI digital channels, and AI Search begins to monetize, EPS will compound rapidly on the reduced share count. - The 5% revenue growth in Q4 is a regulatory air-pocket, not terminal TAM saturation. - The 'Free-99' AI scribe strategy acts as a predatory moat, destroying competitor unit economics. - $317M in trailing FCF validates the accounting reality, mitigating the CFO departure risk. - A $500M open-market buyback provides a hard floor and mathematically forces future EPS growth. - The implied valuation is highly realistic; it requires no multiple expansion, only the mathematical realization of cash flow and float reduction.

Bull case

The base case accelerates as venture-backed AI competitors collapse under Doximity's predatory free pricing, granting the company an absolute monopoly over clinical documentation. Health systems begin mass-adopting the enterprise Clinical AI Suite, creating a massive, sticky SaaS revenue stream independent of volatile pharma marketing budgets. - Competitor capitulation solidifies Doximity as the terminal physician OS. - Enterprise SaaS contracts bypass the pharma-budget regulatory ceiling. - Operating margins snap back to the mid-50s as AI compute costs achieve economies of scale. - The multiple re-rates from a distressed value proxy to a premium AI healthcare platform.

Bear case

The CFO's departure is revealed to be the tip of an accounting irregularity, triggering an SEC probe just as structural drug-pricing reforms permanently impair pharma marketing TAM. The 'AI investment year' proves to be a sunk-cost fallacy, with compute costs permanently destroying the historical 50% operating margins. - Accounting investigations shatter institutional trust and halt the buyback program. - TrumpRx permanently caps pharma ad spend, turning the 5% growth into negative growth. - AI compute costs scale linearly rather than logarithmically, crushing FCF generation. - The stock experiences severe multiple contraction down to a mid-single-digit P/E.

Sentiment and regime

Greed and fear sentiment: -0.8
Expected volatility regime: moderate
Convergence-cycle position: capitulation

Broader narrative

Current crowd consensus: The consensus treats Doximity as a broken, ex-COVID growth darling that has hit a permanent wall. The media and sell-side analysts focus on the deceleration to 5% revenue growth in Q4 FY26, attributing it to irreversible pharma budget cuts under the TrumpRx regime. The narrative is heavily weighted by the recent EPS miss, the 'AI investment year' margin compression, and the sudden departure of the CFO, painting a picture of a company desperately pivoting to AI while its core advertising business decays.
Alpha-gap assessment: The variant perception lies in the misdiagnosis of the margin compression. The crowd sees structural decay; I see an aggressive, cash-funded moat-building exercise. By absorbing the compute costs to offer ambient AI scribing for free, Doximity is starving venture-backed competitors and locking up the physician network. Furthermore, the governance red flag of the CFO's exit is forensically neutralized by the undeniable reality of the balance sheet: you cannot fake $317M in trailing free cash flow while simultaneously executing a $500M open-market buyback. The market is pricing DOCS for terminal decline, ignoring a pristine 7.5% FCF yield.
Convergence catalyst: The convergence will trigger in late 2026/early 2027 (Q3/Q4 FY27 earnings) when pharmaceutical budgets unfreeze for the new calendar year. The combination of normalized pharma ad spend, initial monetization metrics from AI Search, and the mathematically accretive impact of the $500M buyback will force a violent upward repricing.
Macro-regime alignment: Stagflation and higher-for-longer rates are hostile to pre-profit growth stocks, but highly advantageous to debt-free, cash-gushing monopolies. Doximity's 49% FCF margin and zero leverage make it uniquely resilient in the Warsh regime, as it does not rely on external capital markets to fund its operations or its massive buyback.

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Predatory FREE 99 AI Scribe	By offering its ambient AI scribe tool for free to verified clinicians, Doximity is executing a classic predatory pricing strategy. This deliberately incinerates the unit economics of venture-backed competitors who charge monthly SaaS fees, starving them of oxygen. More importantly, it permanently locks physicians into the Doximity walled garden, fortifying its 80%+ market share and cementing its platform as the daily operating system for clinical workflows.	Not available%	+45.0%
Aggressive Float Retirement	The company authorized a $500M open-ended share repurchase program in early 2026. At the current distressed market capitalization of roughly $4.26B, this capital allocation maneuver can accretively retire nearly 12% of the outstanding float. Because the balance sheet carries zero debt and generates over $300M in annual free cash flow, this buyback provides a mathematically hard floor under the stock price and artificially forces EPS growth even if top-line revenue temporarily stalls.	Not available%	+35.0%
AI Search Monetization	Doximity has aggressively transitioned over 300,000 clinicians to its Doximity Ask (DoxGPT) platform. The next phase of the 'AI investment year' is monetizing this utility via sponsored medical search and targeted clinical answers. This transitions the company from a static newsfeed advertising model into high-intent search monetization, effectively becoming the Google of clinical reference and opening a multi-billion dollar Total Addressable Market completely independent of standard display budgets.	Not available%	+30.0%
Pharma Spend Consolidation	When macroeconomic and regulatory pressures shrink overall marketing budgets, pharmaceutical companies do not cut indiscriminately; they cut analog, low-ROI channels (like physical sales reps) and consolidate spend into the highest-ROI, most measurable digital choke points. As the undisputed digital monopoly for verified physician access, Doximity will capture a disproportionate share of a smaller overall pie once the initial regulatory shock of TrumpRx is digested.	Not available%	+25.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Trumprx Budget Freeze	The implementation of 'TrumpRx' and aggressive White House MFN agreements in late 2025 created extreme regulatory whiplash for the top 20 pharmaceutical companies. This caused an immediate freeze in upfront digital marketing budget commitments, directly resulting in Doximity's Q4 FY26 revenue growth decelerating to 5%. Regulatory opacity regarding future drug pricing will cause pharma to authorize spend on a trailing, quarter-by-quarter basis rather than committing to lucrative annual contracts.	Not available%	-25.0%
CFO Departure AND Insider Sales	The abrupt medical leave and subsequent resignation of the CFO in early 2026, paired with a history of advantageous insider equity sales, is a canonical red flag. While the presence of massive GAAP free cash flow mitigates the probability of outright accounting fraud, abrupt C-suite turnover always commands a governance risk premium. Until a permanent CFO is seated and a clean audit cycle is completed, institutional investors will apply a discount to the multiple.	Not available%	-20.0%
Warsh FED RATE Regime	The transition to the Warsh Fed and the persistence of war-driven stagflation guarantees a higher-for-longer cost of capital. Growth-oriented healthcare technology equities face intense multiple compression in this regime. Even though Doximity is highly profitable, the broader sector de-rating forces the stock to trade closer to its terminal cash-flow yield rather than a speculative revenue multiple, capping upside momentum in the near term.	Not available%	-15.0%
AI Compute Margin DRAG	To execute the 'Free-99' AI scribe strategy and build out Doximity Ask, the company is absorbing massive LLM inference and compute costs. This 'AI investment year' caused a 58% year-over-year spike in R&D, compressing operating margins from 55% to 45%. Until the underlying inference costs decline or the new tools generate offsetting revenue, this operational drag will structurally impair near-term EPS and limit P/E multiple expansion.	Not available%	-15.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Enterprise Workflow SAAS Upsell	Doximity successfully pivots from purely pharma-sponsored marketing to hard enterprise SaaS contracts, selling its full Clinical AI Suite (Ask, Scribe, Dialer) directly to major health networks on a per-seat basis. This structurally transforms the income statement, replacing volatile ad budgets with sticky, recurring hospital infrastructure revenue.	25.0%	+50.0%
Ambient Scribe Competitor Capitulation	Venture-backed ambient AI scribe startups, facing predatory free pricing from Doximity and a closed IPO window, exhaust their runway and capitulate. This grants Doximity an uncontested monopoly over clinical documentation, allowing them to eventually introduce premium enterprise tiers to health systems with zero pricing resistance.	35.0%	+40.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Accounting Irregularity SEC Probe	The abrupt departure of the CFO is revealed to be linked to aggressive revenue recognition, capitalization of software development costs, or fraudulent user-metric reporting. An SEC investigation is announced, shattering institutional trust, invalidating the historical financials, and causing a catastrophic multiple collapse.	10.0%	-60.0%
Permanent Pharma Disintermediation	Structural drug-pricing reform (TrumpRx) permanently destroys the margin profile of the US pharmaceutical industry, forcing a permanent, structural reduction in drug marketing budgets. Rather than a temporary delay, the TAM for Doximity's core advertising product shrinks irrevocably.	20.0%	-40.0%

Step-by-step forecast path

Michael Burry forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_0022348c-1b47-5e9c-92d7-87cbd2fc0afe__sb6__20260705152647
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	October 2, 2026	+4.0%	22.73	Q2 FY27 earnings reveal continued margin pressure from AI compute costs, but the $500M buyback execution puts a hard floor under the stock. Pharma budgets remain tight but demonstrate stabilization compared to the Q4 shock.
2	January 2, 2027	+8.0%	24.55	January bookings indicate that pharma budgets are unfreezing for the new calendar year. Doximity reports initial, promising engagement metrics for its sponsored AI Search product, hinting at successful monetization.
3	April 2, 2027	+12.0%	27.50	Q4 FY27 results deliver a double-beat. The 'Free-99' AI scribe strategy forces competitor consolidation, and the reduced share count dramatically amplifies EPS growth. The variant perception is validated.
4	July 2, 2027	+5.0%	28.87	Solid Q1 FY28 performance. Operating margins begin to expand sequentially as the heaviest AI infrastructure build-out is lapped. Institutional rotation back into GARP healthcare names provides a tailwind.
5	October 2, 2027	-3.0%	28.01	Broader market volatility and temporary profit-taking after a strong 12-month run. Sector-wide multiple compression affects digital health equities, though Doximity's FCF yield limits the drawdown.
6	January 2, 2028	+6.0%	29.69	A strong calendar year-end pharma budget flush drives top-line upside. Doximity Ask establishes itself as a material revenue contributor, proving the AI investment was a highly accretive strategic pivot.
7	April 2, 2028	+8.0%	32.06	Q4 FY28 earnings confirm a definitive return to double-digit revenue growth. EPS jumps sharply due to the compounding effect of organic growth layered over a significantly reduced outstanding float.
8	July 2, 2028	+4.0%	33.35	Steady institutional accumulation continues. The stock is fully re-rated from a distressed value trap back to a high-quality compounder, trading fundamentally on its pristine 50%+ FCF margins.
9	October 2, 2028	-5.0%	31.68	General market sell-off related to US election cycle volatility and fears of new healthcare pricing regulations. The core thesis remains intact, and management uses the dip to accelerate share repurchases.
10	January 2, 2029	+7.0%	33.90	Enterprise upsell gains momentum. Major health systems begin signing direct SaaS contracts for the full Clinical AI Suite, diversifying Doximity's revenue base away from purely pharma-sponsored advertising.
11	April 2, 2029	+10.0%	37.29	The FY29 annual report shows FCF margins crossing 52%. The board announces a new, massive share repurchase authorization, signaling immense confidence in the durability of the platform's economics.
12	July 2, 2029	+5.0%	39.15	Telehealth and ambient scribe integrations make Doximity the de facto operating system for US physicians. Pricing power over pharma sponsors reaches its peak due to the absolute monopoly on verified physician attention.
13	October 2, 2029	+3.0%	40.33	User growth decelerates as the TAM becomes fully saturated (>90% of US clinicians onboarded). Top-line growth is now driven entirely by ARPU expansion and enterprise SaaS seat licenses.
14	January 2, 2030	+6.0%	42.74	AI-driven targeted advertising proves to deliver unprecedented ROI for pharmaceutical companies, allowing Doximity to seamlessly push through price increases on its core sponsorship products despite macro headwinds.
15	April 2, 2030	+8.0%	46.16	FY30 results showcase massive EPS expansion. The market capitulates to the reality that Doximity is an impenetrable, high-margin utility toll bridge for the US healthcare system.
16	July 2, 2030	-4.0%	44.32	A mild macroeconomic cyclical slowdown leads to a slight contraction in overall healthcare marketing spend, resulting in a minor top-line miss, though cash flow remains highly robust.
17	October 2, 2030	+4.0%	46.09	The company's automated buyback grid aggressively supports the stock during the Q3 dip. The balance sheet remains an absolute fortress with zero debt and expanding cash reserves.
18	January 2, 2031	+5.0%	48.39	Stabilization and re-acceleration. New product verticals, such as automated prior authorization and integrated clinical trial recruitment, begin to gain meaningful commercial traction.
19	April 2, 2031	+7.0%	51.78	FY31 wrap-up. The five-year transformation from a basic networking application to an indispensable, AI-driven clinical operating system is complete. EPS has more than doubled from the FY26 trough.
20	July 2, 2031	+4.0%	53.85	The stock trades at a premium multiple appropriate for a terminal monopoly asset generating 50%+ free cash flow margins. The investment thesis has fully converged with market pricing.

Advisor and configuration

Advisor: michael_burry__the_vulture__google_gemini_3_1_pro__20260201_preview_release
Persona: Michael Burry
Archetype: The Vulture
Model: (February 01, 2026) Preview Release
Provider: Google
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: michael_burry__the_vulture__google_gemini_3_1_pro__20260201_preview_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: michael_burry__the_vulture__google_gemini_3_1_pro__20260201_preview_release RESEARCHER Forecast Assembly
Input format: Latest Close Price with Stats and Fundamentals
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Michael Burry advisor methodology

Configuration components

aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_efec62e4-24c0-556a-8070-775c69b97643 (global_context)
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4 (task_guidelines)

Back to advisor navigation

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check access View Base plan Return to latest AI Consensus